Abstract

Improved genome-editing via oviductal nucleic acid delivery (i-GONAD) is a technique capable of inducing genomic changes in preimplantation embryos (zygotes) present within the oviduct of a pregnant female. i-GONAD involves intraoviductal injection of a solution containing genome-editing components via a glass micropipette under a dissecting microscope, followed by in vivo electroporation using tweezer-type electrodes. i-GONAD does not involve ex vivo handling of embryos (isolation of zygotes, microinjection or electroporation of zygotes, and egg transfer of the treated embryos to the oviducts of a recipient female), which is required for in vitro genome-editing of zygotes. i-GONAD enables the generation of indels, knock-in (KI) of ~ 1 kb sequence of interest, and large deletion at a target locus. i-GONAD is usually performed on Day 0.7 of pregnancy, which corresponds to the late zygote stage. During the initial development of this technique, we performed i-GONAD on Days 1.4–1.5 (corresponding to the 2-cell stage). Theoretically, this means that at least two GONAD steps (on Day 0.7 and Day 1.4–1.5) must be performed. If this is practically demonstrated, it provides additional options for various clustered regularly interspaced palindrome repeats (CRISPR)/Caspase 9 (Cas9)-based genetic manipulations. For example, it is usually difficult to induce two independent indels at the target sites, which are located very close to each other, by simultaneous transfection of two guide RNAs and Cas9 protein. However, the sequential induction of indels at a target site may be possible when repeated i-GONAD is performed on different days. Furthermore, simultaneous introduction of two mutated lox sites (to which Cre recombinase bind) for making a floxed allele is reported to be difficult, as it often causes deletion of a sequence between the two gRNA target sites. However, differential KI of lox sites may be possible when repeated i-GONAD is performed on different days. In this study, we performed proof-of-principle experiments to demonstrate the feasibility of the proposed approach called “sequential i-GONAD (si-GONAD).”

Highlights

  • Gene editing technologies, such as the clustered regularly interspaced short palindrome repeats (CRISPR)/Caspase 9 (Cas9) system, have been frequently employed as convenient and efficient tools for performing gene modification in various biological systems [1,2]

  • The embryo must be transfected twice with the genome-editing components. To assess whether this event occurs after si-genome-editing via oviductal nucleic acids delivery (GONAD), we used two fluorescent (FITC- or rhodamine-labeled) dextrans to determine the numbers of zygotes that exhibit both fluorescein isothiocyanate-conjugated (FITC)- and rhodamine-derived fluorescence when they are subjected to si-GONAD

  • I-GONAD was performed on Day 0.7 females using FITC-dextran or rhodamine-dextran

Read more

Summary

Introduction

Gene editing technologies, such as the clustered regularly interspaced short palindrome repeats (CRISPR)/Caspase 9 (Cas9) system, have been frequently employed as convenient and efficient tools for performing gene modification in various biological systems [1,2]. Carrying genome-editing components or by subjecting the zygotes to EP in the presence of rAAV-6 carrying genome-editing components All these procedures require ex vivo handling of embryos, which involves subjecting the zygotes derived from in vitro fertilization (IVF), or those freshly isolated from the pregnant females to genome-editing prior to egg transfer into the oviducts of recipient females. These techniques involve labor-intensive and time-consuming ex vivo handling of embryos

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call